dc.contributor.author | ROBERTS, Ian S. D. | |
dc.contributor.author | Cattran, Daniel C. | |
dc.contributor.author | COPPO, Rosanna | |
dc.contributor.author | FEEHALLY, John | |
dc.contributor.author | Herzenberg, Andrew M. | |
dc.contributor.author | Barbour, Sean J. | |
dc.contributor.author | Espino-Hernandez, Gabriela | |
dc.contributor.author | Reich, Heather N. | |
dc.date.accessioned | 2021-03-02T20:10:30Z | |
dc.date.available | 2021-03-02T20:10:30Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Barbour S. J. , Espino-Hernandez G., Reich H. N. , COPPO R., ROBERTS I. S. D. , FEEHALLY J., Herzenberg A. M. , Cattran D. C. , "The MEST score provides earlier risk prediction in IgA nephropathy", KIDNEY INTERNATIONAL, cilt.89, sa.1, ss.167-175, 2016 | |
dc.identifier.issn | 0085-2538 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_00ae69b5-7bd0-49d6-abd4-f5796e3c8e43 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/6456 | |
dc.identifier.uri | https://doi.org/10.1038/ki.2015.322 | |
dc.description.abstract | The Oxford Classification of IgA nephropathy (IgAN) includes the following four histologic components: mesangial (M) and endocapillary (E) hypercellularity, segmental sclerosis (S) and interstitial fibrosis/tubular atrophy (T). These combine to form the MEST score and are independently associated with renal outcome. Current prediction and risk stratification in IgAN requires clinical data over 2 years of follow-up. Using modern prediction tools, we examined whether combining MEST with cross-sectional clinical data at biopsy provides earlier risk prediction in IgAN than current best methods that use 2 years of follow-up data. We used a cohort of 901 adults with IgAN from the Oxford derivation and North American validation studies and the VALIGA study followed for a median of 5.6 years to analyze the primary outcome (50% decrease in eGFR or ESRD) using Cox regression models. Covariates of clinical data at biopsy (eGFR, proteinuria, MAP) with or without MEST, and then 2-year clinical data alone (2-year average of proteinuria/MAP, eGFR at biopsy) were considered. There was significant improvement in prediction by adding MEST to clinical data at biopsy. The combination predicted the outcome as well as the 2-year clinical data alone, with comparable calibration curves. This effect did not change in subgroups treated or not with RAS blockade or immunosuppression. Thus, combining the MEST score with cross-sectional clinical data at biopsy provides earlier risk prediction in IgAN than our current best methods. | |
dc.language.iso | eng | |
dc.subject | İç Hastalıkları | |
dc.subject | Nefroloji | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ÜROLOJİ VE NEFROLOJİ | |
dc.title | The MEST score provides earlier risk prediction in IgA nephropathy | |
dc.type | Makale | |
dc.relation.journal | KIDNEY INTERNATIONAL | |
dc.contributor.department | The University Of British Columbia , , | |
dc.identifier.volume | 89 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 167 | |
dc.identifier.endpage | 175 | |
dc.contributor.firstauthorID | 88213 | |